Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On March 31, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for 2024 and provided a business update.</li><li>Following the release of favorable safety and tolerability results for CDI-988, the company's novel, broad-spectrum protease inhibitor being developed for the treatment of noroviruses and coronaviruses, we anticipate topline results from the high-dose healthy volunteer cohort in the second quarter of 2025 and for a human challenge study as a norovirus treatment and prophylaxis later in 2025.</li><li>Cocyrstal's Phase 2a influenza human challenge study of CC-42344, the company's development candidate for the treatment of pandemic and seasonal influenza A infections, is continuing after the company reported a lower than expected influenza infection rates among study participants.</li></ul>

On March 31, 2025, Cocrystal Pharma, Inc. (COCP) announced financial results for 2024 and provided a business update.Following the release of favorable safety and tolerability results for CDI-988, the company's novel, broad-spectrum protease inhibitor being developed for the treatment of noroviruses and coronaviruses, we anticipate topline results from the high-dose healthy volunteer cohort in the second quarter of 2025 and for a human challenge study as a norovirus treatment and prophylaxis later in 2025.Cocyrstal's Phase 2a influenza human challenge study of CC-42344, the company's development candidate for the treatment of pandemic and seasonal influenza A infections, is continuing after the company reported a lower than expected influenza infection rates among study participants.

COCP: Norovirus Challenge Study Planned for 2025 